Indications for Use
Treatment and prevention of influenza and acute respiratory viral infections (ARVI); treatment of viral hepatitis A, B, C; herpetic infection; cytomegalovirus infection; as part of combination therapy for infectious-allergic and viral encephalomyelitis (multiple sclerosis, leukoencephalitis, uveoencephalitis, meningoencephalitis), urogenital and respiratory chlamydial infections.
To reduce the degree of immunosuppression as part of combination therapy for diseases accompanied by secondary induced immunodeficiencies (caused by exposure to ionizing radiation, cytostatic agents, surgical interventions, etc.) requiring immunocorrection.
Children aged 7 to 18 years: treatment of influenza and acute respiratory viral infections.
Composition of Amixin
Active substance: tilorone.
Each tablet contains tilorone 0.06 g (60 mg).
Excipients: calcium hydrogen phosphate dihydrate, hypromellose (hydroxypropyl methylcellulose), microcrystalline cellulose, povidone, croscarmellose sodium, potato starch, polyethylene glycol (macrogol), talc, colloidal anhydrous silicon dioxide, calcium stearate, titanium dioxide (E171), candurin (titanium dioxide (E171), potassium aluminosilicate (E555)), synthetic mixed red dye (hypromellose, microcrystalline cellulose, titanium dioxide (E171), Ponceau 4R lake (E124), indigo carmine lake (E132), sunset yellow FCF lake (E110)).
Contraindications
- Hypersensitivity to the active substance or any component of the medicinal product
- Pregnancy and breastfeeding
- Children under 7 years of age
Adverse Reactions
Skin and subcutaneous tissue: allergic reactions including angioedema, rash (including urticaria), skin hyperemia, dry skin, itching.
Gastrointestinal tract: bitter taste in the mouth, dyspeptic symptoms (epigastric pain, nausea, heartburn), diarrhea.
General disorders: weakness, lethargy, decreased appetite, short-term fever.
Method of Administration
The medicinal product is taken orally after meals.
Adults
Influenza and ARVI treatment: 125 mg daily for the first 2 days, then 125 mg every 48 hours. Total course dose: 750 mg.
Influenza and ARVI prevention: 125 mg once weekly for 6 weeks.
Viral hepatitis A treatment: 125 mg twice daily on day 1, then 125 mg every 48 hours. Total course dose: 1.25 g.
Viral hepatitis A prevention: 125 mg once weekly for 6 weeks.
Acute hepatitis B: 125 mg daily for the first 2 days, then 125 mg every 48 hours. Total course dose: 2 g (up to 2.5 g in prolonged cases).
Chronic hepatitis B: 250 mg daily for the first 2 days, then 125 mg every 48 hours. Initial dose: 2.5 g. Then 125 mg weekly. Total dose: 3.75–5 g.
Acute hepatitis C: 125 mg daily for the first 2 days, then 125 mg every 48 hours. Total course dose: 2.5 g.
Chronic hepatitis C: 250 mg daily for the first 2 days, then 125 mg every 48 hours. Initial dose: 2.5 g. Then 125 mg weekly. Total course dose: 5 g.
Herpetic and cytomegalovirus infections: 125 mg daily for the first 2 days, then 125 mg every 48 hours. Total course dose: 2.5 g.
Neuroviral infections: 125 mg daily for the first 2 days, then 125 mg every 48 hours. Total course dose: 1.5–1.75 g.
Chlamydial infections: 125 mg daily for the first 2 days, then 125 mg every 48 hours. Total course dose: 1.25 g.
Immunodeficiency states: 125–250 mg once weekly for 6 weeks. Maximum course dose: 1.5 g. Treatment may be repeated after a 4-week interval.
Children aged 7–18 years
Uncomplicated influenza or ARVI: 60 mg once daily on days 1, 2, and 4. Total course dose: 180 mg.
Complicated influenza or ARVI: 60 mg once daily on days 1, 2, 4, and 6. Total course dose: 240 mg.
Special Precautions
Pregnancy and breastfeeding: contraindicated due to lack of clinical data.
Children: not recommended for children under 7 years of age.
Effect on driving: does not affect reaction speed.
Overdose of Amixin
No cases of Amixin IC overdose have been reported.
Drug Interactions
Compatible with antibiotics and standard treatments for viral and bacterial infections.
Storage Conditions of Amixin
Store in the original packaging at a temperature not exceeding 25 °C. Keep out of reach of children.









Reviews
There are no reviews yet.